Management & Regulatory

The ability to reprogram living organisms to produce high-value chemicals and materials has transitioned from a niche academic pursuit to the cornerstone of a new economic paradigm. Instead of relying on the extraction of finite fossil fuels, industries are increasingly looking toward the

Ivan Kairatov is a seasoned Biopharma expert with a distinguished career at the intersection of medical technology and research and development. With deep roots in evaluating how innovative surgical systems transition from clinical trials to the operating room, he brings a unique perspective on the

The persistent threat of tuberculosis remains a formidable challenge for global health initiatives, claiming over a million lives annually despite being a condition that medical professionals have been able to cure for seventy-five years. While pharmaceutical interventions are widely available and

The pharmaceutical industry stands at a precarious crossroads where the very technologies promising to cure incurable diseases also threaten to dismantle the digital foundations of intellectual property protection. GlaxoSmithKline currently finds itself navigating this complex landscape by

The integrity of a nation's healthcare system remains fundamentally tethered to the efficacy of its pharmaceutical oversight, yet Nigeria currently faces a systemic crisis that threatens to undermine public health safety. While the government often highlights specific enforcement milestones as

The global healthcare landscape is currently undergoing a massive transformation as medical institutions move away from traditional, reactive care toward a proactive, data-driven approach that anticipates patient needs before they become critical. This transition relies heavily on a new generation